within Pharmacolibrary.Drugs.ATC.L;

model L01XX33
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.00046166666666666665,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.455,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008666666666666666,
    Tlag           = 19.2,            
    Vdp             = 0.167,
    k12             = 54.0,
    k21             = 54.0
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XX33</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor nonsteroidal anti-inflammatory drug (NSAID) used primarily for the relief of pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute pain. It is widely approved and available in multiple countries for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects, both sexes, after single oral dose administration.</p><h4>References</h4><ol><li><p>Pal, A, et al., &amp; Gobburru, J (2017). Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers. <i>Clinical drug investigation</i> 37(10) 937–946. DOI:<a href=\"https://doi.org/10.1007/s40261-017-0548-6\">10.1007/s40261-017-0548-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28748412/\">https://pubmed.ncbi.nlm.nih.gov/28748412</a></p></li><li><p>Silberstein, S, et al., &amp; Kunkel, T (2023). Celecoxib Oral Solution and the Benefits of Self-Microemulsifying Drug Delivery Systems (SMEDDS) Technology: A Narrative Review. <i>Pain and therapy</i> 12(5) 1109–1119. DOI:<a href=\"https://doi.org/10.1007/s40122-023-00529-7\">10.1007/s40122-023-00529-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37329440/\">https://pubmed.ncbi.nlm.nih.gov/37329440</a></p></li><li><p>Paulson, SK, et al., &amp; Karim, A (2001). Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. <i>The Journal of pharmacology and experimental therapeutics</i> 297(2) 638–645. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11303053/\">https://pubmed.ncbi.nlm.nih.gov/11303053</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XX33;
